-
Acute Myeloid Leukemia (AML) –KOLs Insight | Competitive Intelligence | Market Forecast 2033
Price range: $11,800.00 through $20,000.00
Price range: $5,900.00 through $10,000.00Select options This product has multiple variants. The options may be chosen on the product pageThe research study conducted by Mellalta Meets provides insights into the AML market dynamics, treatment trends, and key opportunities in the G7 regions. It highlights the need for novel targeted therapies, the potential of biomarker strategies, and the significant market opportunity for drug developers targeting the AML population. The study serves as a comprehensive resource for understanding the current landscape and future prospects of AML treatment.
-
Peripheral T-cell lymphoma (PTCL)| Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
Price range: $6,989.00 through $20,967.00Select options This product has multiple variants. The options may be chosen on the product pageMellalta’s analysts estimate that the United States market is expected to show rapid growth, mainly attributed to, the launch of Adcetris in the front-line setting and expected approval of the potential therapies in the pipeline during the forecast period (2021-2030). Through this, the market size is set to show an extensive jump and grow at a CAGR of 15.3%
-
Anti-Neutralizing Antibodies (NAbs) Gene Therapies-Pipeline Analytics 2022
Price range: $2,700.00 through $8,100.00Select options This product has multiple variants. The options may be chosen on the product pageAnti-Neutralizing Antibodies (NAbs) Gene Therapies report covers the Anti-Neutralizing Antibodies (NAbs) Gene Therapies market opportunity providing Key Competitive Analysis, 20+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports covers pipeline product analysis by stage of development, competitive landscape by phases, companies, therapy area and indication by phases. NAbs inhibitor’s reports add a value in terms of providing the description of clinical stage product with respect to their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers and challenges.
Call us today: +1 (304) 470-2225
English
You can use WPML or Polylang and their language switchers in this area.